MBX Biosciences (MBX) Capital Expenditures (2023 - 2026)

MBX Biosciences has reported Capital Expenditures for 4 years, with the latest figure at $437000.0 in Q1 2026.

• Quarterly Capital Expenditures fell 12.95% year-over-year to $437000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$39000.0 (down 103.54% YoY) and the FY2025 annual result came in at $26000.0, down 97.03% from the prior year.
• Capital Expenditures advanced to $437000.0 in Q1 2026 per MBX's latest filing, from -$1.1 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $712000.0 in Q3 2024 and troughed at -$1.1 million in Q4 2025.
• A 4-year average of $146600.0 and a median of $254000.0 in 2024 frame the typical range for Capital Expenditures.
• The widest YoY moves for Capital Expenditures: up 215.76% in 2025, down 1306.52% in 2025.
• Over 4 years, Capital Expenditures stood at $129000.0 in 2023, then retreated by 28.68% to $92000.0 in 2024, then plunged by 1306.52% to -$1.1 million in 2025, then surged by 139.37% to $437000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $437000.0, -$1.1 million, and $399000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.